In the first quarter of 2013, Aegerion Pharmaceuticals (NASDAQ:AEGR) posted its first revenues ever. At its recent price of about $74, the company's shares are trading at about 1,732 times trailing twelve month sales. If you think that's a bit steep for a biotech with a single product, you're not alone.
(click to enlarge)
I'm going to show you why this company's lone product, recently approved in the US for the treatment of one ultra-rare disease, makes Aegerion's recent price seem not just reasonable, but undervalued.
Good news from the EU
On June 3, Aegerion Pharmaceuticals made a special call to announce a very positive response [pdf] from the European Medicines Agency's [EMA] Committee for Medicinal...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|